NCT06362369 2025-09-17A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy7 Hills Pharma, LLCPhase 1/2 Recruiting126 enrolled
NCT05704985 2025-05-29Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ TumorsDEKA BiosciencesPhase 1 Active not recruiting39 enrolled
NCT02897765 2021-02-25A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder CancerBioNTech SEPhase 1 Completed34 enrolled